Aeras Global TB Vaccine Foundation and Crucell N.V. Announce Start of a Tuberculosis Vaccine Clinical Trial in the United States. Aeras Global TB Vaccine Foundation Commits a Further USD 5M to the Development of the Tuberculosis Vaccine

Leiden, The Netherlands, December 21, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced it will receive up to USD 5 million from Rockville, Maryland-headquartered Aeras Global TB Vaccine Foundation to support the advanced development of the candidate AdVac®- and PER.C6®-based tuberculosis vaccine.